and family linkage studies (Sparkes et al., 1983 ) the RBI gene was assigned to chromosome region 13ql4. Cavenee et al. (1983) demonstrated that, in individuals who were constitutionally heterozygous for chromosome 13 loci, their tumours were homo-or hemi-zygous at the same loci. This 'loss of heterozygosity' was presumed to lead to 'exposure' of the recessive disease causing mutation in the Rb gene. In heterditary cases, only copies of the chromosome carrying the mutant gene were retained in tumour cells (Cavenee et al., 1985) thus providing formal proof of Knudson's hypothesis. Possible mechanisms for loss of the normal allele included mitotic recombination and non-disjunction. Since loss of RB1 function is required for tumorigenesis the normal function of the gene appears to be to maintain normal cellular growth control. This controlling function has resulted in this class of cancer genes being called 'tumour suppressor genes' or 'recessive cancer genes'. The majority of human familial cancer predisposition syndromes fall into this class.
Chromosome 13-specific DNA probes were isolated and subregionally localised using panels of somatic cell hybrids (Lalande et al., 1984; Dryja et al., 1986) . One of these DNA clones lay within a coding sequence and a candidate gene was isolated (Friend et al., 1986; Fung et (Mitchell & Cowell, 1989) and others (Higgins et al., 1989) (Friend et al., 1987; Bookstein et al., 1988) and produces an mRNA 4.7 kb long. The exon/intron structure of the gene has been characterised (McGee et al., 1989) and the amino acid sequence of the gene product determined. Despite this information there are no common motifs to indicate its function.
In the majority of tumours there is loss of heterozygosity for the 13q14 region and therefore, presumably homozygosity for the specific predisposing mutation. In some cases, however, tumorigenesis will result from independent mutations in the two homologous genes. In the UK, however, the majority of tumours are treated in situ using cryosurgery or radiotherapy which makes obtaining tumour tissue difficult. Those researchers who have been able to perform extensive analysis of the RNA from tumours have usually had the foresight to develop cell lines in vitro (Gallie et al., 1982 (1988, 1989) have identified mutations in tumour cells using RNAase protection techniques which is a means of detecting mismatches between tumour RNA and the normal sequence. Point mutations, splice junction mutations, and small deletions could all be detected. Although more than 20 tumours were analysed, however, no single region of the gene was preferentially involved. To overcome problems associated with RNA analysis analysed the DNA sequence of RBI in tumour cells exon-by-exon.
The availability of the normal 250 base pair sequence on either side of each exon (McGee et al., 1989) meant that specific oligonucleotides could be designed and each exon/ intron region amplified using the polymerase-chain-reaction (PCR). The amplified product was then sequenced and mutations were identified by comparison with the normal sequence in seven tumours. If the same mutation was present in normal constitutional cells from the same patient that individual was identified as a gene carrier. This analysis also identified mutations such as premature stop codons in the flanking intron region which would not have been found in the RNA transcript. (Cowell et al., 1987) . We have noted in our series (Cowell et al., 1987; Onadim et al., 1990) (Cowell et al., 1988) . Currently 50% of 13q-patients are only unilaterally affected which is unrelated to the size of the deletion. This finding apparently contradicts the prediction that predisposed individuals will develop multifocal, bilateral tumours. One explanation is that other mutations within the deletion are lethal and potential tumour precursor cells fail to proliferate. This explanation presumably accounts for reports of 13q-patients who have not developed retinoblastoma (Cowell et al., 1988; Wilson et al., 1987) .
The RB gene product Some RB1 mutations result in abnormal transcripts or the absence of transcripts Fung et al., 1987) , whereas other tumours produce apparently normal mRNA (Goddard et al., 1988) . The use of monoclonal antibodies to the RBI protein (pRB) however, demonstrated that, in the majority of cases, even if an mRNA is produced in tumour cells pRB is not (Whyte et al., 1988; Horowitz et al., 1990 ).
That pRB is apparently confined to the nucleus and binds to DNA suggests that it is a regulatory protein. However, it is expressed in a wide variety of cells, in addition to developing retinal cells. Addition of certain growth factors to quiescent cells causes them to divide. The RB1 gene must be inactivated for tumorigenesis. Does RB, therefore, restrict cell proliferation? pRB exists in phosphorylated and unphosphoryated forms, the phosphorylated form appearing in the GI stage of the cell cycle and declines after S phase suggesting a role in cell division (Mihara et al., 1989) . Cells induced to terminally differentiate (thereby losing their proliferative potential) also lose their ability to phosphorylate pRB. The only indication of how pRB functions biochemically to regulate cell growth follows the observation that it binds to the transforming proteins of certain DNA viruses. These proteins can over-ride the normal growth regulations of the cell. Thus, pRB binds to Ela of adenovirus (Whyte et al., 1988) , large-T antigen of SV40 (Ludlow et al., 1989) , and E7 of human papilloma virus (Dyson et al., 1989) . Binding these proteins inactivates pRB and it is the unphosphorylated form which is targetted (Ludlow et al., 1989) . These observations imply that, by maintaining pRB in the unphosphorylated form, cells stay quiescent. Phosphorylating or inactivating pRB pushes the cells through mitosis which is required by the DNA viruses for self-replication. Whilst providing an opportunity to study the control of the cell cycle it is still not clear, however, how this gene functions to induce differentiation in primitive retinal cells. Although the position of naturally occurring mutations within the gene is apparently random, those preventing Ela binding apparently cluster in the 10-12 exons flanking the large central intron (Hu et al., 1990) . There have been too few reports to date, however, to draw any definite conclusions as to the significance of this observation.
Second tumours
Individuals predisposed to Rb are also at a significantly higher risk than the general population to the development of second, non-ocular tumours especially osterosarcoma and soft tissue sarcomas (Abramson et al., 1984; Draper et al., 1986) . These tumours may arise in the radiation treatment field, but also occur both in unirradiated sites and in patients who have not received radiation at all. In these tumours the RB1 gene shows frequent structural abnormalities (Toguchida et al., 1988; Friend et al., 1987) implicating it in pathogenesis. Abnormalities of RBI have also been detected in tumours not associated with Rb predisposition including bladder cancer (Horowitz et al., 1989) , small cell lung carcinoma (Harbour et al., 1988) and breast cancer . Abnormalties in these tumours, however, are infrequent and more likely reflect tumour progression than tumour initiation.
Suppression of malignancy by RB1
If functional inactivation of both copies of RB1 is a prerequisite for tumorigenesis, the introduciton of a normal gene should restore the normal phenotype. Huang et al. (1988) reported that introducing RB1 via a retroviral vector changed the in vitro phenotype of one Rb cell line with a homozygous deletion of RB1. These cells assumed characteristics suggesting differentiation and, unlike the parental cell line failed to produce tumours in nude mice. The same was also true in an osteosarcoma cell line deficient in RB1 function. Surprisingly the tumorigenicity in a prostate cancer cell line was also suppressed after introduction of the retrovirus-linked gene (Bookstein et al., 1990) . Clearly, to understand the function of RB1 in retinal development an animal model would be desirable, but to date none exists. The creation of transgenic mice that develop Rb-like tumours following introduction of the SV40 genome is noteworthy. However the integration site is on chromosome 4 and not chromosome 14 which is the site of the endogenous mouse RBI gene (Windle et al., 1990) .
Future prospects
The cloning of the retinoblastoma gene is already having a major influence on the clinical management of the disease. Soon unequivocal identification of all gene carriers in Rb families will be possible and, thereby, allow resources to be concentrated on those patients who need them. Direct analysis of the RBI gene sequence, as described, will eventually allow us to determine whether new patients represent sporadic cases or carry germ-line mutations. The identification of specific predisposing mutations in individuals will also undoubtedly improve our understanding of gene function. As more data accumulates and patterns emerge it may be that molecular pathology will be able to predict the course of this disease in terms of invasiveness/prognosis, whether bilateral, unilateral or regressed tumours will arise and whether patients will be susceptible to second tumours. Unravelling the intricate way in which this gene controls the development of several different tissues and its influence on the cell cycle, however, is still in the very early stages.
